<div id="readability-page-1"><p>Viking Therapeutics (NASDAQ:VKTX - Get Free Report) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.07), Zacks reports.</p><div><p><span></span><span>Get <strong>Viking Therapeutics</strong> alerts:</span></p></div><h2>Viking Therapeutics Trading Up 1.4 %</h2><ul><li>Viking Therapeutics Stock Pops But Struggles to Hold Gains</li></ul><p>VKTX traded up $0.36 during trading on Wednesday, hitting $25.84. 4,145,398 shares of the company's stock were exchanged, compared to its average volume of 4,045,729. The stock has a 50 day moving average price of $26.75 and a 200 day moving average price of $41.30. Viking Therapeutics has a 1 year low of $18.92 and a 1 year high of $81.86. The firm has a market cap of $2.90 billion, a P/E ratio of -25.84 and a beta of 0.84. </p><h2>Wall Street Analyst Weigh In</h2><p>VKTX has been the topic of a number of research analyst reports. HC Wainwright  reiterated a &#34;buy&#34; rating and set a $102.00 target price on shares of Viking Therapeutics in a research report on Thursday, April 17th. The Goldman Sachs Group began coverage on shares of Viking Therapeutics in a report on Tuesday, April 8th. They issued a &#34;neutral&#34; rating and a $30.00 price target on the stock. B. Riley  reiterated a &#34;buy&#34; rating and set a $96.00 target price (down previously from $109.00) on shares of Viking Therapeutics in a report on Friday, February 7th. Scotiabank began coverage on Viking Therapeutics in a research note on Thursday, February 13th. They set a &#34;sector outperform&#34; rating and a $102.00 price objective on the stock. Finally, Maxim Group reduced their target price on shares of Viking Therapeutics from $120.00 to $70.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, February 7th. One analyst  has rated the stock with a sell rating, two have issued  a hold rating, ten have assigned  a buy rating and one  has assigned  a strong buy rating to the company. According to data from MarketBeat, the stock  has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $89.75.</p><ul><li>Which Healthcare Stock Is the Best Buy Right Now?</li></ul><p><b>Get Our Latest Stock Analysis on Viking Therapeutics</b></p><h2>Insider Activity at Viking Therapeutics</h2><p>In other news, Director Sarah Kathryn Rouan purchased 1,240 shares of the company's stock in a transaction that occurred on Monday, March 31st. The shares were purchased at an average price of $24.15 per share, with a total value of $29,946.00. Following the purchase, the director now directly owns 1,240 shares of the company's stock, valued at approximately $29,946. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 4.70% of the stock is owned by insiders. </p><h2>About Viking Therapeutics</h2> (Get Free Report)<ul><li>MarketBeat Week in Review – 03/17 - 03/21</li></ul><p>Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.</p><h2>Read More</h2><ul><li>Five stocks we like better than Viking Therapeutics</li><li>Are Penny Stocks a Good Fit for Your Portfolio?</li><li>Can IBM’s Q1 Earnings Spark a Breakout for the Stock?</li><li>What is a Low P/E Ratio and What Does it Tell Investors?</li><li>S&amp;P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry?</li><li>Where to Find Earnings Call Transcripts</li><li>Fundamentally Sound, These 5 Stocks Sold Off Anyway</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Viking Therapeutics Right Now?</h2><p>Before you consider Viking Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.</p><p>While Viking Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

VKTX

<p>Viking Therapeutics (NASDAQ:VKTX) reported a quarterly EPS of ($0.41), missing estimates by $0.07. The stock traded up 1.4% to $25.84, with a market cap of $2.90 billion. Analysts have mixed ratings, with a consensus rating of "Moderate Buy" and a target price of $89.75. Insider activity includes a purchase of 1,240 shares by Director Sarah Kathryn Rouan. The company focuses on developing therapies for metabolic disorders, with its lead candidate VK2809 in Phase IIb trials.</p>

Viking Therapeutics (NASDAQ:VKTX) Posts Earnings Results, Misses Estimates By $0.07 EPS